ArticleWorld journal of gastroenterology2011
Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma.
Article in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.PloS one · 2014Pooled it
- Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma and its Clinical Implications in Systemic Chemotherapy.International journal of medical sciences · 2025Review
- SFRP1 mediates cancer-associated fibroblasts to suppress cancer cell proliferation and migration in head and neck squamous cell carcinoma.BMC cancer · 2024Article
- Epigenetic regulation in lung cancer.MedComm · 2023Review
- The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?International journal of environmental research and public health · 2023Review
- Review
- Expression of Tumor Suppressor SFRP1 Predicts Biological Behaviors and Prognosis: A Potential Target for Oral Squamous Cell Carcinoma.Biomolecules · 2022Article
- Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck.Frontiers in medicine · 2022Review
- The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy.Biomarker research · 2021Review
- Blood-based biomarkers for early detection of esophageal squamous cell carcinoma.World journal of gastroenterology · 2020Review
- Identification of key regulators in parathyroid adenoma using an integrative gene network analysis.Bioinformation · 2020Article
- Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma: Biological and Clinical Implications.Frontiers in oncology · 2020Review
- Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis.Oncology letters · 2019Article
- Cell-free DNA testing: future applications in gastroenterology and hepatology.Therapeutic advances in gastroenterology · 2019Review
- Overexpression of long noncoding RNA LINC01419 in esophageal squamous cell carcinoma and its relation to the sensitivity to 5-fluorouracil by mediating GSTP1 methylation.Therapeutic advances in medical oncology · 2019Article
- Dickkopf Homolog 3Frontiers in oncology · 2019Article
- Epigenetic silencing of ZNF132 mediated by methylation-sensitive Sp1 binding promotes cancer progression in esophageal squamous cell carcinoma.Cell death & disease · 2018Article
- DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.Oncology research · 2018Article
- Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.Journal of applied genetics · 2017Article
- Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo detect the effects of plasma DNA methylation of Wnt antagonists/inhibitors on recurrence of esophageal squamous cell carcinoma (ESCC).
methodsWe used methylation-specific polymerase chain reaction to detect hypermethylation of the promoter of four Wnt antagonists/inhibitors (SFRP-1, WIF-1, DKK-3 and RUNX3) using DNA from the plasma of ESCC patients (n = 81) and analyzed the association between promoter hypermethylation of Wnt pathway modulator genes and the two-year recurrence of ESCC.
resultsHypermethylation of SFRP-1, DKK-3 and RUNX-3 was significantly associated with an increased risk of ESCC recurrence (P = 0.001, 0.003 and 0.001 for SFRP-1, DKK-3 and RUNX3, respectively). Patients carrying two to three methylated genes had a significantly elevated risk of recurrence compared with those not carrying methylated genes (odds ratio = 15.69, 95% confidential interval: 2.97-83). The area under the receiver operating characteristic curve (AUC) was 77.1 for ESCC recurrence prediction (sensitivity = 66.67 and specificity = 83.3). When combining methylated genes and the clinical stage, the AUC was 83.69, with a sensitivity of 76.19 and a specificity of 83.3.
conclusionThe status of promoter hypermethylation of Wnt antagonists/inhibitors in plasma may serve as a non-invasive prognostic biomarker for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.